TCF7 and B-cell chronic lymphocytic leukemia: In relapsed and refractory CLL patients, we found there was no significant difference in the effect of first-line treatment regimens on TCF1 expression except for a slight upward trend in the ibrutinib group, which may be related to the small number of cases in different groups (Table S1).